Abstract
Platelet aggregation plays a central role in the pathophysiology of acute coronary syndromes, and the platelet glycoprotein IIb/IIIa receptor has been identified as the critical final mediator of this process. Antagonists of this receptor used parenterally during both acute coronary syndromes and percutaneous coronary interventions reduce the likelihood of subsequent major cardiac complications. However, after the treatment period little further benefit accrues. Based on these observations and that of the significant benefit of aspirin in cardiovascular secondary prevention, oral glycoprotein IIb/IIIa receptor antagonists are being evaluated with the goal of extending the benefit of glycoprotein IIb/IIIa inhibition into chronic secondary prevention. This paper will review the results of the SYMPHONY study of one such oral agent, sibrafiban, and the current state of the oral glycoprotein IIb/IIIa inhibitor field.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 111-119 |
| Number of pages | 9 |
| Journal | Journal of Thrombosis and Thrombolysis |
| Volume | 10 |
| Issue number | 2 |
| State | Published - 2000 |
Fingerprint
Keywords
- Coronary artery disease
- Glycoprotein IIb/IIIa inhibitors
- Platelet aggregation inhibitors
- Platelets
- Secondary prevention
ASJC Scopus subject areas
- Hematology
- Cardiology and Cardiovascular Medicine
Cite this
Oral glycoprotein IIb/IIIa antagonists : New insights from the SYMPHONY trial. / McGuire, Darren K; Newby, L. K.
In: Journal of Thrombosis and Thrombolysis, Vol. 10, No. 2, 2000, p. 111-119.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Oral glycoprotein IIb/IIIa antagonists
T2 - New insights from the SYMPHONY trial
AU - McGuire, Darren K
AU - Newby, L. K.
PY - 2000
Y1 - 2000
N2 - Platelet aggregation plays a central role in the pathophysiology of acute coronary syndromes, and the platelet glycoprotein IIb/IIIa receptor has been identified as the critical final mediator of this process. Antagonists of this receptor used parenterally during both acute coronary syndromes and percutaneous coronary interventions reduce the likelihood of subsequent major cardiac complications. However, after the treatment period little further benefit accrues. Based on these observations and that of the significant benefit of aspirin in cardiovascular secondary prevention, oral glycoprotein IIb/IIIa receptor antagonists are being evaluated with the goal of extending the benefit of glycoprotein IIb/IIIa inhibition into chronic secondary prevention. This paper will review the results of the SYMPHONY study of one such oral agent, sibrafiban, and the current state of the oral glycoprotein IIb/IIIa inhibitor field.
AB - Platelet aggregation plays a central role in the pathophysiology of acute coronary syndromes, and the platelet glycoprotein IIb/IIIa receptor has been identified as the critical final mediator of this process. Antagonists of this receptor used parenterally during both acute coronary syndromes and percutaneous coronary interventions reduce the likelihood of subsequent major cardiac complications. However, after the treatment period little further benefit accrues. Based on these observations and that of the significant benefit of aspirin in cardiovascular secondary prevention, oral glycoprotein IIb/IIIa receptor antagonists are being evaluated with the goal of extending the benefit of glycoprotein IIb/IIIa inhibition into chronic secondary prevention. This paper will review the results of the SYMPHONY study of one such oral agent, sibrafiban, and the current state of the oral glycoprotein IIb/IIIa inhibitor field.
KW - Coronary artery disease
KW - Glycoprotein IIb/IIIa inhibitors
KW - Platelet aggregation inhibitors
KW - Platelets
KW - Secondary prevention
UR - http://www.scopus.com/inward/record.url?scp=0033754471&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033754471&partnerID=8YFLogxK
M3 - Article
VL - 10
SP - 111
EP - 119
JO - Journal of Thrombosis and Thrombolysis
JF - Journal of Thrombosis and Thrombolysis
SN - 0929-5305
IS - 2
ER -